Journal of Experimental & Clinical Cancer Research 2008, 27:33 http://www.jeccr.com/content/27/1/33 Postoperative adjuvant chemotherapy was administered; the patient received five courses of COP+PEG-liposomal doxorubicin according to the following schedule: Cyclo- phosphamide 750 mg/m2 i.v. (day 1), Vincristine 1.4 mg/ m2 (day 1), PEG-liposomal doxorubicin (Caelyx) 40 mg/ m2 i.v (day 1) and Prednisone 100 mg po days 1–5, every 3 weeks. Results No hematological toxicity was reported, but WHO grade 3 skin toxicity was observed. In particular the patient after the fourth cycle developped a palmar erytrodysesthesia with painful erytema that was attributed to PEG-lipo- somal doxorubicin and consequently we reduced at 70% the dose of Caelyx in the last course of treatment. The ery- trodysesthesia was transitory and successful treated with mild dose of prednisone per os. A total body CT scan performed one month after the last course of chemotherapy was negative for lymphoaden- ophaty (Figure 4) and previous subpleural fibrosis was not modified. Three months after chemotherapy, the patient also underwent total body 18-F-FDG PET/CT that showed no residual tumor activity (Figure 5). The patient is disease free at 5 years after the diagnosis with CT scan negative. Discussion Follicular dendritic cell sarcoma is a rare neoplasm that can involve lymph nodes or extranodal sites [2,4,5]. Once FDC sarcoma is suspected from the histologic findings, immunohistochemical stains for follicular cell differenti- ation must be performed to avoid the potential for misdi- agnosis. CD21 and CD35, directed respectively against the C3d and C3b receptors, together with CD23 and clusterin nFCeieggrauvtriicveael4froergiroensiCduTalscmaans,sone month after chemotherapy, Cervical region CT scan, one month after chemo- therapy, negative for residual mass PFoigsuitirvee 3staining for CD23 Positive staining for CD23 sTFhoigotuwalrinbego5dnyo1r8e-sFidDuGal PtuEmTotrhraecetivmitoynths after chemotherapy, Total body 18-FDG PET three months after chemo- therapy, showing no residual tumor activity Page 3 of 4 (page number not for citation purposes)